['metastatic melanoma', 'stage iii melanoma', 'stage iv melanoma']
['indoximod', 'ipilimumab', 'nivolumab', 'pembrolizumab']

        Inclusion Criteria:

          -  Unresectable Stage III or Stage IV melanoma.

          -  Patients must have measurable disease, defined as lesions that can be accurately
             measure in in 2 perpendicular diameters with at least one diameter > 20mm and the
             other >10mm on conventional CT or MRI or 10mm x 10 mm by spiral CT.

          -  No systemic treatment in the previous 28 days.

          -  Age ≥18 years. Because no dosing or adverse event data are currently available on the
             use of ipilimumab or indoximod in patients <18 years of age, children are excluded
             from this study.

          -  ECOG performance status ≤2 (Karnofsky ≥60% )

          -  Patients with known brain metastases will only be eligible after their tumors have
             been treated with definitive resection and/or radiotherapy and they are neurologically
             stable for at least 1 month off steroids.

        Exclusion Criteria:

          -  Patients who have had molecular targeted therapy (including vemurafenib) or
             radiotherapy within 4 weeks prior to entering the study or those who have not
             recovered from adverse events due to agents administered more than 4 weeks earlier.

          -  Patients who have had prior therapy with immune checkpoint inhibition or or indoximod
             are excluded from the trial.

          -  Any other cancer, unless the patient has been disease-free for ≥5 years

          -  Patients with laboratory evidence of pancreatitis are excluded.

          -  Patients with autoimmune disease

          -  Chronic use of immune-suppressive drugs (ie, systemic corticosteroids used in the
             management of cancer or non-cancer related illnesses, eg, COPD).
      